drugset / Trial / NCT00073255
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
Phase 1
Completed
12 enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hokt3g1 (ALA-ALA) | Unknown | — | Intravenous |